Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Moody's
MCO
5
Apple
AAPL
HK Stock MarketDetailed Quotes
02898 SUNHO BIO-B
- 4.510
- +0.010+0.22%
Market Closed Apr 30 16:08 CST
706.57MMarket Cap-8.19P/E (TTM)
4.560High4.510Low2.20KVolume4.560Open4.500Pre Close9.98KTurnover0.00%Turnover RatioLossP/E (Static)156.67MShares15.42052wk High1.28P/B706.57MFloat Cap3.00052wk Low--Dividend TTM156.67MShs Float15.420Historical High--Dividend LFY1.11%Amplitude3.000Historical Low4.536Avg Price200Lot Size--Div YieldTTM--Div Yield LFY
About SUNHO BIO-B Company
我们成立于2018年,是一家专注于发现、开发和商业化用于治疗癌症和自身免疫性疾病的生物制剂的临床阶段生物制药公司。我药们拥有三种核心产品,即IAH0968、IAP0971及IAE0972,均为自主研发。IAH0968是一种抗体依赖性细胞介导的细胞毒性(「ADCC」)增强型单克隆抗体(「mAb」),我们已启动针对胆道癌(「BTC」)、结直肠癌(「CRC」)及胃癌(「GC」)的II期临床试验。IAP0971及IAE0972均为抗体细胞因子,我们已完成针对晚期实体瘤(包括非小细胞肺癌(「NSCLC」)及CRC)的I期临床试验。 截至2024年12月31日,我们有九种管线产品,除核心产品外,其中三种处于临床阶段,亦专注于癌症治疗。 本公司股份于2024年5月24日于联交所上市。本集团自本公司全球发售获得的所得款项净额约为391.6百万港元(经扣除包销佣金及相关成本及开支)。
Company Profile
Symbol02898
Company NameSUNHO BIO-B
ISINKYG8572S1021
Listing DateMay 24, 2024
Issue Price13.50
Shares Offered34.15M share(s)
FoundedMay 14, 2021
Registered AddressCayman Islands
Chairmanfeng zhang
Secretarykaitingxuchunqin huang
Audit Institution德勤·关黄陈方会计师行
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficePO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of Business香港铜锣湾勿地臣街1号时代广场2座31楼
Fiscal Year Ends12-31
Employees130
MarketHong Kong motherboard
Phone(025)85666008
Emailharvest@sunho-bio.com;chenzi@sunho-bio.com
Websitehttp://www.sunho-bio.com.cn
Business Sunho Biologics Inc是一家主要从事生物技术的研发和生产的公司。该公司主要从事发现、开发和商业化生物制剂,透过直接调节先天性和适应性免疫系统来调节免疫微环境。该公司拥有三种核心产品,分别为IAH0968、IAP0971及IAE0972。IAH0968是一种抗体依赖性细胞介导的细胞毒性增强型单株抗体,IAP0971及IAE0972均为抗体细胞激素。
Company Executives
- Name
- Position
- Salary
- feng zhang
- Chairman of the Board, Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members, Authorized Representative
- --
- liusong yin
- CEOs, Executive Director, Chief Scientific Officer
- --
- xiaoling jiang
- VP, Executive Director
- --
- rongkui fan
- Non-executive Directors
- --
- xiangrong chen
- Independent Non-Executive Director, Chairman of the Audit Committee
- --
- lan feng
- Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
- --
- luwen shi
- Independent Non-Executive Director, Audit Committee Members, Remuneration Committee Members, Nomination Committee Members
- --
- chunqin xu
- Chief Financial Officer, Joint Company Secretary
- --
- dongcheng jiang
- VP
- --
- kaiting huang
- Joint Company Secretary, Authorized Representative
- --
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts